[Combination treatment in pulmonary arterial hypertension].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Kramer MR;Kramer MR
  • Source:
    Harefuah [Harefuah] 2011 Apr; Vol. 150 (4), pp. 383-8, 417.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    Hebrew
  • Additional Information
    • Source:
      Publisher: Israel Medical Association Country of Publication: Israel NLM ID: 0034351 Publication Model: Print Cited Medium: Print ISSN: 0017-7768 (Print) Linking ISSN: 00177768 NLM ISO Abbreviation: Harefuah Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tel Aviv : Israel Medical Association
    • Subject Terms:
    • Abstract:
      In recent years, there has been a marked improvement in the treatment of pulmonary arterial hypertension (PAH) due to the development of targeted therapies. There are now several treatment options available--oral, inhaled, and those delivered by subcutaneous or intravenous methods. These treatments have greatly improved patient survival, which in the past was 2.5 years on average. Efficient treatment choice generally proceeds from oral therapies--PDE-5 inhibitors (sildenafil) and endothelin receptor antagonists (bosentan or ambrisentan)--to inhaled prostanoids (iloprost) or subcutaneous (treprostinil). Intravenous prostacyclins are used in treating the more severe cases. The different pathways of action of each class of drugs allow a synergistic effect of combination therapy similar to malignancy or patients in congestive heart failure. The updated treatment algorithm includes combinations of therapies that target different pathways. This article will review the literature regarding combination therapy for the treatment of PAH. Combining PAH therapies that target different pathways is now a well-established treatment option, based on numerous international clinical trials, and offers new hope to patients suffering from this severe disease.
    • Accession Number:
      0 (Antihypertensive Agents)
    • Publication Date:
      Date Created: 20111215 Date Completed: 20111222 Latest Revision: 20141120
    • Publication Date:
      20240829
    • Accession Number:
      22164922